Terns Pharmaceuticals, Inc. is an American pharmaceutical company focused on developing therapies for liver diseases, including non-alcoholic steatohepatitis (NASH). With a medium risk rating score of 26.2, Terns Pharmaceuticals is dedicated to ESG principles in its clinical-stage biopharmaceutical research.